At a glance
| Aliases | Bepecin; PL-14736 |
|---|---|
| Size | 15 amino acids |
| Evidence center | Animal and laboratory research |
| Human evidence | Small and limited reports |
| FDA status | No approved BPC-157 drug |
Overview
BPC-157 is also called bepecin or PL-14736. It attracts interest for tendon, muscle and gastrointestinal recovery, but the volume of animal publications should not be mistaken for a large body of reliable human trials. FDA’s 2026 evaluation identified small human reports, a limited ulcerative-colitis meeting abstract and substantial gaps in route-specific safety. A registered healthy-volunteer study does not supply a usable efficacy result merely because it appears in a trial registry. Claims that the molecule universally heals tissues go well beyond the available controlled human evidence.
How it works
Preclinical studies report effects on cell migration, stress survival and tissue-repair signaling. In rat tendon-cell experiments, BPC-157 altered FAK–paxillin signaling and fibroblast outgrowth; these are mechanistic findings in experimental tissue, not a validated human receptor-based treatment model. Different injury systems and routes can produce different exposures, so an observed laboratory pathway does not establish a safe or effective clinical regimen.
What laboratory research supports
A tendon study found improved fibroblast migration, outgrowth and survival under experimental stress, alongside activation of FAK and paxillin. These results identify hypotheses for further investigation; they do not demonstrate faster return to sport or durable tendon healing in patients.
Supporting sources [1]
What the human record can establish
FDA’s 2026 assessment found that the small ulcerative-colitis evidence was insufficient for an effectiveness conclusion and that human safety information could not adequately characterize the proposed products. Small uncontrolled reports cannot separate treatment effects from natural recovery or concurrent care.
Supporting sources [2]
Known gaps and plausible product risks
The absence of a well-defined adverse-event rate is a gap, not reassurance. FDA highlighted uncertainty about immune reactions, peptide-related impurities and characterization. Sterility, composition and exposure also differ between proposed oral, local and injectable products.
Supporting sources [2]
Compounding review is not approval
BPC-157 was considered in the 2026 Pharmacy Compounding Advisory Committee process. Such review concerns compounding policy and does not establish approval of a drug as safe and effective. This record therefore avoids treating an advisory development as an approved therapeutic indication.
Is BPC-157 the same as TB-500?
No. They are different substances with different sequences and evidence. A combination marketed under a recovery nickname does not establish the benefit or safety of either component, and findings for one cannot be assigned to the other.
Supporting sources [2]
Common questions
Do animal tendon findings prove faster recovery in people? No. Tendon-cell and animal experiments establish research hypotheses; they do not measure reliable clinical healing, return to sport or long-term human safety.
Does a compounding advisory discussion approve BPC-157? No. FDA's review of bulk substances and any advisory recommendation are separate from approval of a finished medicine for a specific indication.
Reading this profile
Jurisdiction: United States — no FDA-approved BPC-157 medicine; compounding-policy review is distinct from drug approval.. Molecular class: Synthetic pentadecapeptide research compound.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- BPC-157 effects on tendon outgrowth, survival and migration ↗Original research · Checked 2026-10-27
- FDA 2026 evaluation of BPC-157-related bulk drug substances ↗Regulatory source · Checked 2026-10-27
- FDA July 2026 Pharmacy Compounding Advisory Committee meeting ↗Regulatory source · Checked 2026-10-27